DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dexrazoxane
Dexrazoxane
Thames Valley Chemotherapy Regimens Sarcoma
Cardiotoxicity of Doxorubicin Is Mediated Through Mitochondrial Iron Accumulation
ZINECARD® (Dexrazoxane) for Injection Regimens
Guideline for the Management of Extravasation
Upfront Dexrazoxane for the Reduction of Anthracycline-Induced
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases
Anthracycline Chemotherapy and Cardiotoxicity
Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
TCRM-3694-Anthracycline Extravasation
(12) United States Patent (10) Patent No.: US 9,125,835 B2 Sinko Et Al
Dexrazoxane Decreases the Cardiotoxic Effects of Doxorubicin in Osteosarcoma Patients Without Increasing Mortality from Secondary Malignant Neoplasms
4740350.Pdf (3.641Mb)
1 Efficacy and Safety of Glucarpidase for Routine
Medical Specialty Drug List
List Item Dexrazoxane
Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury
General Oxidative Stress During Doxorubicin-Induced Cardiotoxicity in Rats: Absence of Cardioprotection and Low Antioxidant Efficiency of Alpha-Lipoic Acid
Summary of Product Characteristics, Labelling and Package Leaflet
Top View
Drug Consumption at Wholesale Prices in 2017 - 2020
Procedure Codes, Section 3
Lists of Medicinal Products for Rare Diseases in Europe*
Neonatal Murine Engineered Cardiac Tissue Toxicology Model Impact Of
Topoisomerase IIB–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane
Bc Cancer Chemotherapy Preparation and Stability
Appendix B - Product Name Sorted by Applicant
Clinical Policy: Dexrazoxane (Zinecard, Totect)
Savene, INN-Dexrazoxane
The Cardioprotective Effect of Dexrazoxane (Cardioxane) Is Consistent with Sequestration of Poly(ADP-Ribose) by Self-Assembly and Not Depletion of Topoisomerase 2B
Dicobalt Edetate(BAN, Rinn) Digoxin-Specific Antibody Fragments
DEPARTMENT of HEALTH and HUMAN SERVICES
Product Monograph
Management of Cardiac Toxicity Induced by Chemotherapy
Research Article Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury
Pharmacological Management of Anticancer Agent Extravasation
Improved Targeting of Brain Tumors Using Dexrazoxane Rescue of Topoisomerase II Combined with Supralethal Doses of Etoposide and Teniposide’
Specialty Payment Model Opportunities and Assessment
Zinecard (Dexrazoxane for Injection)
Addenbrooke's Hospital, CAMBRIDGE
A Novel Strategy for the Delivery of Doxorubicin to Reduce Cardio Toxicity
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Synergistic Inhibition of Tumor Cell Proliferation by Metformin and Mito-Metformin in the Presence of Iron Chelators
Pagina Tuttostoria
Chelation Therapy Effective Date: 2/1/17
AHFS Pharmacologic-Therapeutic Classification System
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
TCRM-3694-Anthracycline Extravasation
Evolvement of EU Regulations on Innovative Medicines’ Was Accepted for Poster Presentation at the 77Th International Pharmaceutical Federation
Dexrazoxane Art 31 Referral
DEXRAZOXANE for INJECTION of Dexrazoxane Was Excreted in the Urine
NHS England Evidence Review: Dexrazoxane for Preventing
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Drugs & Therapy
Savene, INN-Dexrazoxane
Transdermal Deferoxamine Prevents Pressure-Induced Diabetic Ulcers
Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
Effects of Dexrazoxane on Doxorubicin-Related Cardiotoxicity and Second
Dexrazoxane May Prevent Doxorubicin-Induced DNA Damage
WHO List of Priority Medical Devices for Cancer Management
DRUG NAME: Mitoxantrone
ATC Code Title
Zinecardâ (Dexrazoxane for Injection) US Package Insert FDA Approved Labeling for S-006
Acute Exercise Protects Against Doxorubucin Cardiotoxicity Karen Y